Bivalent RSV+HMPV protein vaccine clinical trials

Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older

This study is testing a new vaccine for adults aged 60 and over. It aims to protect against two common chest infections, RSV and HMPV. Researchers want to see how well it works and if it's safe. Half of the volunteers will get the vaccine, and half will get a dummy injection (placebo).